Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
6.23
+0.06 (0.97%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Silence Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.84 | 0.56 | 43.26 | 31.64 | 21.66 | 16.79 | |
Revenue Growth (YoY) | -96.86% | -98.71% | 36.71% | 46.12% | 29.01% | 124.07% |
Cost of Revenue | 0.17 | 0.22 | 11.81 | 12.87 | 13.46 | 10.08 |
Gross Profit | 0.67 | 0.34 | 31.45 | 18.78 | 8.19 | 6.7 |
Selling, General & Admin | 21.69 | 22.34 | 26.88 | 26.22 | 25.68 | 27.05 |
Research & Development | 47.31 | 67.75 | 67.88 | 56.94 | 43.55 | 41.59 |
Other Operating Expenses | 1.32 | 1.32 | - | - | - | - |
Total Operating Expenses | 70.32 | 91.42 | 94.77 | 83.16 | 69.23 | 68.64 |
Operating Income | -78.41 | -91.08 | -63.32 | -64.38 | -61.04 | -61.94 |
Interest Income | - | - | - | - | - | 0.01 |
Interest Expense | - | - | - | - | - | -0.07 |
Other Non-Operating Income (Expense) | 3.38 | 2.48 | 18.86 | 11.11 | 11.39 | - |
Total Non-Operating Income (Expense) | 3.38 | 2.48 | 18.86 | 11.11 | 11.39 | -0.06 |
Pretax Income | -75.03 | -88.6 | -44.46 | -53.27 | -49.65 | -62 |
Provision for Income Taxes | 0.01 | 0.01 | 0.85 | 0.96 | 0.69 | -8.71 |
Net Income | -14.96 | -88.61 | -45.31 | -54.23 | -50.33 | -53.28 |
Net Income to Common | -48.31 | -88.61 | -45.31 | -54.23 | -50.33 | -53.28 |
Shares Outstanding (Basic) | 47 | 47 | 46 | 37 | 32 | 30 |
Shares Outstanding (Diluted) | 47 | 47 | 46 | 37 | 32 | 30 |
Shares Change (YoY) | 0.36% | 2.12% | 24.69% | 15.21% | 8.58% | 8.78% |
EPS (Basic) | -1.62 | -1.89 | -0.99 | -1.47 | -1.56 | -1.80 |
EPS (Diluted) | -1.62 | -1.89 | -0.99 | -1.47 | -1.56 | -1.80 |
Free Cash Flow | -65.62 | -62.33 | -67.85 | -49.52 | -57.22 | 7.43 |
Free Cash Flow Per Share | -1.39 | -1.32 | -1.47 | -1.33 | -1.78 | 0.25 |
Gross Margin | 79.50% | 61.54% | 72.70% | 59.34% | 37.83% | 39.94% |
Operating Margin | -9345.05% | -16292.80% | -146.38% | -203.47% | -281.88% | -369.02% |
Profit Margin | -1782.72% | -15851.90% | -104.74% | -171.37% | -232.44% | -317.44% |
FCF Margin | -7820.74% | -11149.60% | -156.85% | -156.49% | -264.22% | 44.26% |
EBITDA | -77.88 | -90.52 | -62.73 | -63.76 | -60.44 | -61.36 |
EBITDA Margin | -9282.72% | -16193.60% | -145.00% | -201.50% | -279.12% | -365.58% |
EBIT | -78.41 | -91.08 | -63.32 | -64.38 | -61.04 | -61.94 |
EBIT Margin | -9345.05% | -16292.80% | -146.38% | -203.47% | -281.88% | -369.02% |
Effective Tax Rate | -0.01% | -0.01% | -1.90% | -1.79% | -1.39% | 14.06% |